Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Declines By 14.3%

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 9,480,000 shares, a decline of 14.3% from the February 13th total of 11,060,000 shares. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is presently 2.3 days. Approximately 5.7% of the shares of the stock are sold short.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR opened at $0.30 on Friday. The company has a market cap of $51.91 million, a P/E ratio of -3.38 and a beta of 0.39. The business has a fifty day simple moving average of $0.46 and a 200-day simple moving average of $0.54. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Insider Buying and Selling

In related news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock worth $91,198 in the last ninety days. Insiders own 1.62% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XFOR. Verition Fund Management LLC acquired a new stake in shares of X4 Pharmaceuticals in the third quarter worth approximately $30,000. Cantor Fitzgerald L. P. acquired a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $30,000. Atria Wealth Solutions Inc. acquired a new position in shares of X4 Pharmaceuticals in the 4th quarter valued at $44,000. Wells Fargo & Company MN grew its stake in shares of X4 Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock valued at $58,000 after buying an additional 26,763 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares during the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.